Loading...
Guest User
Welcome! Please login.
| IPO Listing At | BSE, NSE |
| IPO Issue Type | Book Build Issue |
| Issue Size | ₹6479.55 Cr |
| Fresh Issue | ₹1250.00 Cr |
| Offer for Sale | ₹5229.55 Cr |
| Face Value | ₹1 Per Equity Share |
| Price Band | ₹1490.00-1500.00 per share |
| Discount | Retail: 0.00 |
| BSE Code | 543245 |
| NSE Code | GLAND |
| Registrar | MUFG Intime India Pvt.Ltd. |
| Lead Managers | Kotak Mahindra Capital Co.Ltd. |
| Allotment Status | |
| DRHP |
| RHP |
| Final Prospectus |
| Anchor List |
 ₹0 A/C OpeningFree MF ₹20F&O Trade ₹0Delivery 1Cr+Customers Open Free Account → |
 ₹0 A/C Opening₹0 AMC Trading Account ₹20F&O Trade ₹20Delivery FreeIPO Apply Open Free Account → |
Disclaimer: GMP is sourced from grey market dealers and is indicative only. Always conduct your own due diligence.
* Allotment, Refund, Demat Credit & Listing dates are tentative and subject to change.
Minimum bid: 10 shares and in multiples thereof
Gland Pharma Ltd, the Hyderabad-based company is one of the fastest-growing generic injectable companies. It manufactures a diversified range of high-quality complex injectables. The company offers products like sterile injectables, oncology, and ophthalmics, complex injectables (peptides, suspensions, hormonal products, long-acting injectables), NCE-1s, First-to-File products, etc.
The company follows a B2B model to sell its products in more than 60 countries including the US, Canada, Australia, India, Europe, etc. Leading pharma companies i.e. Sagent Pharmaceuticals, Apotex Inc. Athnex Pharmaceutical Division, LLC, Fresenius Kabi USA, LLC, etc. are some of the key customers.
It has 7 robust manufacturing units in India comprising 4 finished formulations facilities, 22 production lines, and 3 APIs.
Company Strengths
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Funding incremental working capital requirements of our Company | 769.50 |
| 2 | Funding capital expenditure requirements of our Company | 168.00 |
| 3 | General corporate purposes | 286.47 |
| # | Issue Expenses | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | BRLMs fees and commissions (including underwriting commission, brokerage and selling commission) | 97.34 |
| 2 | Selling commission/processing fee for SCSBs, Sponsor Bank and fee payable to the Sponsor Bank for Bids made by RIBs | 1.04 |
| 3 | Brokerage and selling commission and bidding charges for members of the Syndicate (including their sub-Syndicate Members), Registered Brokers, RTAs and CDPs | 3.12 |
| 4 | Fees payable to the Registrar to the Offer | 0.12 |
| 5 | Fees payable to the other advisors to the Offer | 0.94 |
| 6 | Listing fees, SEBI filing fees, upload fees, BSE & NSE processing fees, book building software fees and other regulatory expenses | 10.27 |
| 7 | Printing and stationery | 1.29 |
| 8 | Advertising and marketing expenses | 9.22 |
| 9 | Fee payable to legal counsels | 10.69 |
| 10 | Miscellaneous | 5.23 |
Last Updated on 19-Nov-2020 20:34:00
